BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

Vanda’s itch therapy misses in atopic dermatitis   Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares tumbled after market close Tuesday after tradipitant missed the primary endpoint in the Phase III EPIONE trial to treat atopic dermatitis in...
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak....
BioCentury | Feb 21, 2020
Politics, Policy & Law

Biopharma industry, academics push back against demands for price controls on COVID-19 countermeasures

The biopharma industry and academics who are developing vaccines and therapies to prevent and treat COVID-19 pushed back Thursday against calls from members of Congress for price controls on medical countermeasures. In a letter to...
BioCentury | Feb 20, 2020
Targets & Mechanisms

Insights on COVID-19 vaccine, mAb development from spike protein structure

A UT Austin and NIH Vaccine Research Center team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. The findings, published in a Science paper Wednesday,...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

With support from HHS, Sanofi is adapting the platform behind its approved flu vaccine to develop a COVID-19 vaccine. A Sanofi (Euronext:SAN; NASDAQ:SNY) spokesperson told BioCentury the company will, at its own expense, develop a...
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
Items per page:
1 - 10 of 8781
BioCentury | Feb 27, 2020
Politics, Policy & Law

Plotting a scientific path to counter COVID-19

In a global online forum Tuesday night, scientific leaders from companies developing vaccines, therapies and diagnostics to address the COVID-19 outbreak discussed opportunities for collaboration, highlighted challenges, and called for sustained global initiatives to create...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

COVID-19: A growing list of new vaccines and therapies in development

As the response to the ongoing COVID-19 outbreak unfolds, BioCentury is tracking the new vaccines and therapeutics in development against the coronavirus and updating the list on an ongoing basis. Repurposed agents being tested for...
BioCentury | Feb 26, 2020
Product Development

Feb. 25 Quick Takes: Vanda’s Phase III miss; plus Iovance; 1st-twoXAR; app for AFib, stroke; ICER-Aetion; new-look Purple Book, and more

Vanda’s itch therapy misses in atopic dermatitis   Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares tumbled after market close Tuesday after tradipitant missed the primary endpoint in the Phase III EPIONE trial to treat atopic dermatitis in...
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

With a call for proposals by the Innovative Medicines Initiative for COVID-19 development programs and a new vaccine development consortium led by a Denmark-based biotech, Europe is ramping up its response to the coronavirus outbreak....
BioCentury | Feb 21, 2020
Politics, Policy & Law

Biopharma industry, academics push back against demands for price controls on COVID-19 countermeasures

The biopharma industry and academics who are developing vaccines and therapies to prevent and treat COVID-19 pushed back Thursday against calls from members of Congress for price controls on medical countermeasures. In a letter to...
BioCentury | Feb 20, 2020
Targets & Mechanisms

Insights on COVID-19 vaccine, mAb development from spike protein structure

A UT Austin and NIH Vaccine Research Center team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. The findings, published in a Science paper Wednesday,...
BioCentury | Feb 19, 2020
Product Development

COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

With support from HHS, Sanofi is adapting the platform behind its approved flu vaccine to develop a COVID-19 vaccine. A Sanofi (Euronext:SAN; NASDAQ:SNY) spokesperson told BioCentury the company will, at its own expense, develop a...
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BioCentury | Feb 14, 2020
Product Development

AML’s growing options

For acute myelogenous leukemia patients, 2017 marked the end of a more than 40 year drought in which chemotherapy was the only treatment option. In the last three years, eight new AML therapies have come...
Items per page:
1 - 10 of 8781